Kodiak Sciences shares double on positive retinal drug trial results

Kodiak Sciences' stock more than doubled after two experimental retinal disease drugs succeeded in an advanced-stage trial, moving the company closer to its first market product. The results are company-reported and not yet peer-reviewed; regulatory approval and commercial launch remain uncertain. This is a company-specific catalyst with no immediate macro-market implications.